80 generics will compete fiercely over the generic market of Celebrex
It is expected that approximately 80-100 generics of the leading product recording KRW 60 billion annual sales in the non-steroidal anti-inflammatory drugs (NASIDs) market, Celebrex, will be fierce among clinic-level medical institutions from the second half of the year as the patent of the produ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
